Home › Funds › Ikarian Capital, LLC › CTNM

Ikarian Capital, LLC position in CTNM

CONTINEUM THERAPEUTICS INC CL A · Health Care

Ikarian Capital, LLC reported holding 807,874 shares of CTNM (CONTINEUM THERAPEUTICS INC CL A) in its Q2 2026 13F filing — a position valued at US$13.2M, representing 2.13% of its reported portfolio and ranking #11 among its reported holdings. Ikarian Capital, LLC has disclosed CTNM holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)807.87K sh
Reported value held$13.24M
Portfolio Weight2.13%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Ikarian Capital, LLC's CTNM position evolved

Ikarian Capital, LLC first disclosed a stake in CTNM in Q4 2025 at 282,874 shares (US$3.2M). The position peaked in Q2 2026 at 807,874 shares, worth US$13.2M. Across 3 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 807,874 shares valued at US$13.2M. Notable position changes include a 186% increase in Q1 2026 (shares rose 25% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 282.87K $3.23M New
Q1 2026 807.87K $10.55M Add
Q2 2026 807.87K $13.24M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CTNM and 13F data

CTNM (CONTINEUM THERAPEUTICS INC CL A) is a Health Care company. 63 other funds we track also report a position in CTNM — the largest reported positions include MONTANOVA CAPITAL, LLC (US$46.6M), JOHNSON & JOHNSON (US$32.4M), GREAT POINT PARTNERS LLC (US$15.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CTNM

All CTNM fund holders →

FAQ

How long has Ikarian Capital, LLC held CTNM?

Ikarian Capital, LLC has disclosed CTNM holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Ikarian Capital, LLC's current position in CTNM?

As of Q2 2026, Ikarian Capital, LLC holds 807.87K shares of CTNM (CONTINEUM THERAPEUTICS INC CL A), valued at $13.24M, representing 2.13% of its reported portfolio and ranking #11.

Has Ikarian Capital, LLC been buying or selling CTNM?

In the latest 13F filing (Q2 2026), Ikarian Capital, LLC held unchanged its position in CTNM. The position peaked in Q2 2026 at 807.87K shares.

Which other funds hold CTNM?

Other major institutional holders of CTNM include MONTANOVA CAPITAL, LLC, JOHNSON & JOHNSON, GREAT POINT PARTNERS LLC, among 63 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.